Initiating antiretrovirals during tuberculosis treatment: A drug safety review

Expert Opinion on Drug Safety

Volumn 10, Issue 4, 2011, Pages 559-574

  Gengiah, Tanuja N ^a   Gray, Andrew L ^a,b   Naidoo, Kogieleum ^a   Karim, Quarraisha Abdool ^a,c  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c Department of Epidemiology ^*  (United States)

Author keywords

drug interactions; HAART; rifamycins; safety HIV; toxicity; tuberculosis

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; COTRIMOXAZOLE; CYTOCHROME P450 3A4; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ETHAMBUTOL; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; ISONIAZID; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PYRAZINAMIDE; RALTEGRAVIR; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; RITONAVIR; SAQUINAVIR; TIPRANAVIR; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION RISK; LIVER DISEASE; LIVER TOXICITY; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA AND VOMITING; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ANIMALS; ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; DRUG INTERACTIONS; DRUG TOXICITY; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 79958802504     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.546783     Document Type: Review

References (134)

1. UNAIDS. AIDS epidemic update December 2009. Available from: http://data.unaids.org/pub/Report/2009/ JC1700-Epi-Update-2009-en.pdf [Cited 28 July 2010]
2. World Health Organization. Global tuberculosis control: a short update to the 2009 report; 2009
3. Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 2010;50(Suppl 3):S201-7
4. Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrugand extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2009;181(1):80-6
5. Habib AG. A clinical and epidemiologic update on the interaction between tuberculosis and human immunodeficiency virus infection in adults. Ann Afr Med 2009;10(3):147-55
6. Di Perri G, Aguilar Marucco D, Mondo A, et al. Drug-drug interactions and tolerance in combining antituberculosis and antiretroviral therapy. Expert Opin Drug Saf 2005;4(5):821-36 (Pubitemid 41246135)
7. McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 2007;196(Suppl 1):S63-75 (Pubitemid 47206086)
8. Abdool-Karim SS, Abdool-Karim Q, Friedland G, et al. Implementing antiretroviral therapy in resource-constrained settings: opportunities and challenges in integrating HIV and tuberculosis care. AIDS 2004;18(7):975-9 (Pubitemid 38591187)
9. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002;16(1):75-83 (Pubitemid 34062184)
10. Chilton D, Edwards SG, Pellegrino P, Miller RF. Factors influencing delay in initiating antiretroviral therapy among HIV infected patients coinfected with tuberculosis. Thorax 2008;63(10):935-6
11. Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004;190(9):1670-6 (Pubitemid 39411018)
12. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010(1):CD000171
13. Hung CC, Chen MY, Hsiao CF, et al. Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS 2003;17(18):2615-22
14. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362(8):697-706
15. Hardman J, Limbird LE, Gilman A. Goodman and Gilmans The pharmacological basis of therapeutics. 10th edition. McGraw-Hill, New York; 2001
16. McIlleron H, Wash P, Burger A, et al. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006;50(4):1170-7
17. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 2004;48(11):4473-5 (Pubitemid 39434921)
18. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis 2004;38(2):280-3 (Pubitemid 38113038)
19. Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997;127(4):289-93 (Pubitemid 27352050)
20. Sommadossi JP. HIV protease inhibitors: pharmacologic and metabolic distinctions. AIDS 1999;13(Suppl 1):S29-40
21. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344(13):984-96 (Pubitemid 32240318)
22. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18(1):84-112 (Pubitemid 28059007)
23. Bonora S, Di Perri G. Interactions between antiretroviral agents and those used to treat tuberculosis. Curr Opin HIV AIDS 2008;3(3):306-12 (Pubitemid 351521015)
24. Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001;40(12):893-905 (Pubitemid 34066687)
25. Washington CB, Duran GE, Man MC, et al. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19(3):203-9
26. Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008;23(2):192-202 (Pubitemid 351257678)
27. Centers for disease control and prevention. Managing drug interactions in the treatment of HIV-related tuberculosis 2007. Available from: http:// www.cdc.gov/tb/TB-HIV-Drugs/default. htm [Cited 20 July 2010]
28. Onyebujoh PC, Ribeiro I, Whalen CC. Treatment options for HIV-associated tuberculosis. J Infect Dis 2007;196(Suppl 1):S35-45 (Pubitemid 47206083)
29. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004;364(9441):1244-51 (Pubitemid 39311345)
30. El-Sadr WM, Perlman DC, Denning E, et al. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis 2001;32(4):623-32 (Pubitemid 32565005)
31. World Health Organization. Treatment of tuberculosis: guidelines for national programmes; 2010
32. Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010;50(9):1288-99
33. Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther 2009;14(8):1039-43
34. Centers for Disease Control and Prevention. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep. 2002:214-15
35. Nardell EA, Rubin EJ. Once upon a time improved intermittent therapy for tuberculosis-fact or fable?. Am J Respir Crit Care Med 2005;172(11):1361-2 (Pubitemid 43069807)
36. Johns Hopkins University. Study of daily rifapentine for pulmonary tuberculosis. Available from http:// clinicaltrials.gov/show/NCT00814671 [Cited 29 November 2010]
37. Centers for disease control and prevention. TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment. Available from http:// clinicaltrials.gov/ct2/show/NCT00694629 [Cited 29 November 2010]
38. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001;40(5):327-41 (Pubitemid 32565595)
39. Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother 2009;64(5):910-28
40. Uttayamakul S, Likanonsakul S, Manosuthi W, et al. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res Ther 2010;7:8
41. Matteelli A, Regazzi M, Villani P, et al. Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr HIV Res 2007;5(3):349-53 (Pubitemid 46785071)
42. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002;41(9):681-90
43. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006;58(6):1299-302 (Pubitemid 44884158)
44. Cohen K, Grant A, Dandara C, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009;14(5):687-95
45. Manosuthi W, Sungkanuparph S, Tantanathip P, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009;48(12):1752-9
46. Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS 2005;19(14):1481-6 (Pubitemid 41400693)
47. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 2006;20(1):131-2 (Pubitemid 41818129)
48. Nyakutira C, Roshammar D, Chigutsa E, et al. High prevalence of the CYP2B6 516G->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008;64(4):357-65
49. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1,2009; 1-139. Available from: http://www. aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf [Cited 20 July 2010]
50. World Health Organization. Rapid Advice. Antiretroviral therapy for HIV infection in adults and adolescents - November 2009. Available from http://www.who.int/hiv/ pub/arv/rapid-advice-art.pdf. [Accessed 30 September 2010]. World Health Organisation, Geneva, Switzerland 2009
51. Cohen K, van Cutsem G, Boulle A, et al. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother 2008;61(2):389-93
52. Ramachandran G, Hemanthkumar AK, Rajasekaran S, et al. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. J Acquir Immune Defic Syndr 2006;42(1):36-41 (Pubitemid 43947944)
53. Avihingsanon A, Manosuthi W, Kantipong P, et al. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antivir Ther 2008;13(4):529-36 (Pubitemid 352016715)
54. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. Available from: http:// whqlibdoc.who.int/publications/2010/ 9789241599764-eng.pdf. [Accessed 21 September 2010]
55. Laureillard D, Prak N, Fernandez M, et al. Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia. HIV Med 2008;9(7):514-18
56. Winston A, Pozniak A, Smith N, et al. Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals? AIDS 2004;18(3):572-4 (Pubitemid 38365890)
57. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008;300(5):530-9
58. Manosuthi W, Mankatitham W, Lueangniyomkul A, et al. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. HIV Med 2008;9(5):294-9 (Pubitemid 351517276)
59. van Oosterhout JJ, Kumwenda JJ, Beadsworth M, et al. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. Antivir Ther 2007;12(4):515-21 (Pubitemid 47041150)
60. Tibotec, Inc. Intelence (Etravirine) full prescribing information 2009. Available from: http://rsc.tech-res.com/Document/ DrugInfoDoc/PI-Etravirine%20 (Intelence)%202-2010.pdf [Cited 28 July 2010]
61. Boffito M, Maitland D, Samarasinghe Y, Pozniak A. The pharmacokinetics of HIV protease inhibitor combinations. Curr Opin Infect Dis 2005;18(1):1-7 (Pubitemid 41716233)
62. Narita M, Stambaugh JJ, Hollender ES, et al. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis. Clin Infect Dis 2000;30(5):779-83
63. Justesen US, Andersen AB, Klitgaard NA, et al. Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. Clin Infect Dis 2004;38(3):426-9 (Pubitemid 38200123)
64. la Porte CJ, Colbers EP, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004;48(5):1553-60 (Pubitemid 38544359)
65. Burger DM, Agarwala S, Child M, et al. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother 2006;50(10):3336-42 (Pubitemid 44527507)
66. Rolla VC, da Silva Vieira MA, Pereira Pinto D, et al. Safety, efficacy and pharmacokinetics of ritonavir 400 mg/saquinavir 400 mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis. Clin Drug Investig 2006;26(8):469-79
67. Haas DW, Koletar SL, Laughlin L, et al. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr 2009;50(3):290-3
68. Mallolas J, Sarasa M, Nomdedeu M, et al. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. HIV Med 2007;8(2):131-4 (Pubitemid 46390850)
69. Acosta EP, Kendall MA, Gerber JG, et al. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother 2007;51(9):3104-10 (Pubitemid 350067515)
70. Tibotec, Inc. Prezista (Darunavir) full prescribing information 2010. Available from: http://rsc.tech-res.com/Document/ DrugInfoDoc/PI-Darunavir%20 (Prezista)%20April%202010.pdf [Cited 27 July 2010]
71. Centers for disease control and prevention. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 2009;58(RR-4):167-84
72. Polk RE, Brophy DF, Israel DS, et al. Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob Agents Chemother 2001;45(2):502-8 (Pubitemid 32105287)
73. Nijland HM, LHomme RF, Rongen GA, et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 2008;22(8):931-5 (Pubitemid 351652243)
74. LHomme R F, Nijland HM, Gras L, et al. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. AIDS 2009;23(7):863-5
75. Elsherbiny D, Ren Y, McIlleron H, et al. Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children. Eur J Clin Pharmacol 2010;66(10):1017-23
76. Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 2009;49(9):1305-11
77. Khachi H, OConnell R, Ladenheim D, Orkin C. Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. J Antimicrob Chemother 2009;64(4):871-3
78. Gray A, Abdool Karim SS, Gengiah TN. Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis-HIV-co-infected patients in resource-constrained settings. AIDS 2006;20(2):302-3
79. Boehringer Ingelheim. Aptivus (tipranavir) full presecribing information. 2010. Available from: http://rsc.tech-res. com/safetyandpharmacovigilance/ PIList. aspx [Cited 29 July 2010]
80. Emmelkamp JM, Rockstroh JK. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions - review of the literature. Eur J Med Res 2007;12(9):409-17 (Pubitemid 350011453)
81. Yost R, Pasquale TR, Sahloff EG. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection. Am J Health Syst Pharm 2009;66(8):715-26
82. Pfizer Labs. Maraviroc full prescribing information. May 2010. Available from: http://rsc.tech-res.com/Document/ DrugInfoDoc/PI-Maraviroc%20 (Selzentry)%20May%202010.pdf [Cited 28 July 2010]
83. Merck Sharpe Dohme. Isentress (raltegravir) full presecribing information. 2010.Available from: http://rsc.tech-res. com/Document/DrugInfoDoc/ PI-Raltegravir%20(Isentress)%20June% 202010.pdf [Cited 28 July 2010]
84. Burger DM, Meenhorst PL, Koks CH, Beijnen JH. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother 1993;37(7):1426-31 (Pubitemid 23202366)
85. Gallicano KD, Sahai J, Shukla VK, et al. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br J Clin Pharmacol 1999;48(2):168-79 (Pubitemid 29349452)
86. South African National Department of Health. Clinical guidelines for the management of HIV and AIDS in adults and adolescents. 2010. Available from: http://www.doh.gov.za/ docs/facts-f.html [Cited 28 July 2010]
87. Droste JA, Verweij-van Wissen CP, Kearney BP, et al. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2005;49(2):680-4 (Pubitemid 40175680)
88. Rodriguez-Novoa S, Alvarez E, Labarga P, Soriano V. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010;9(4):545-59
89. World Health Organization. Global tuberculosis control:surveillance, planning, financing "WHO/HTM/TB/ 2008.393" Geneva; 2008
90. Coyne KM, Pozniak AL, Lamorde M, Boffito M. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 2009;23(4):437-46
91. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368(9547):1575-80 (Pubitemid 44780738)
92. Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007;196(Suppl 1):S86-107
93. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006;44(1 Suppl):S132-9 (Pubitemid 43053889)
94. Marks DJ, Dheda K, Dawson R, et al. Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS 2009;20(5):339-45
95. Aaron L, Saadoun D, Calatroni I, et al. Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect 2004;10(5):388-98 (Pubitemid 38714564)
96. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167(11):1472-7 (Pubitemid 37363354)
97. Pukenyte E, Lescure FX, Rey D, et al. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment. Int J Tuberc Lung Dis 2007;11(1):78-84 (Pubitemid 46101850)
98. Sulkowski MS, Mehta SH, Chaisson RE, et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004;18(17):2277-84 (Pubitemid 39620220)
99. Hoffmann CJ, Charalambous S, Thio CL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007;21(10):1301-8 (Pubitemid 46883484)
100. Westreich DJ, Sanne I, Maskew M, et al. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis 2009;48(11):1617-23
101. Breen RA, Lipman MC, Johnson MA. Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals. AIDS 2000;14(5):615 (Pubitemid 30209704)
102. Boulle A, Orrel C, Kaplan R, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 2007;12(5):753-60 (Pubitemid 47235489)
103. Gonzalez-Duarte A, Cikurel K, Simpson DM. Managing HIV peripheral neuropathy. Curr HIV/AIDS Rep 2007;4(3):114-18 (Pubitemid 47493051)
104. Cohen K, Meintjes G. Management of individuals requiring antiretroviral therapy and TB treatment. Curr Opin HIV AIDS 2010;5(1):61-9
105. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133(1):21-30 (Pubitemid 30432540)
106. Munro SA, Lewin SA, Smith HJ, et al. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 2007;4(7):e238
107. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS 2003;17(4):169-77 (Pubitemid 36444006)
108. Amuha MG, Kutyabami P, Kitutu FE, et al. Non-adherence to anti-TB drugs among TB/HIV co-infected patients in Mbarara Hospital Uganda: prevalence and associated factors. Afr Health Sci 2009;9(Suppl 1):S8-15
109. Kagee A, Remien RH, Berkman A, et al. Structural barriers to ART adherence in Southern Africa: challenges and potential ways forward. Glob Public Health 2010;6:1-15
110. Meintjes G, Lynen L. Prevention and treatment of the immune reconstitution inflammatory syndrome. Curr Opin HIV AIDS 2008;3(4):468-76
111. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008;8(8):516-23 (Pubitemid 352005824)
112. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998;158(1):157-61 (Pubitemid 28337174)
113. Manosuthi W, Van Tieu H, Mankatitham W, et al. Clinical case definition and manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2009;23(18):2467-71
114. Sharma SK, Dhooria S, Barwad P, et al. A study of TB-associated immune reconstitution inflammatory syndrome using the consensus case-definition. Indian J Med Res 2010;131:804-8
115. Baalwa J, Mayanja-Kizza H, Kamya MR, et al. Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active anti-retroviral therapy in Uganda. Afr Health Sci 2008;8(3):190-5
116. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007;21(3):335-41 (Pubitemid 46175045)
117. Burman W, Weis S, Vernon A, et al. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 2007;11(12):1282-9
118. Muller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010;10(4):251-61
119. Valin N, Pacanowski J, Denoeud L, et al. Risk factors for unmasking immune reconstitution inflammatory syndrome presentation of tuberculosis following combination antiretroviral therapy initiation in HIV-infected patients. AIDS 2010;24(10):1519-25
120. Michailidis C, Pozniak AL, Mandalia S, et al. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther 2005;10(3):417-22 (Pubitemid 41151019)
121. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010;24(15):2381-90
122. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009;4(5):e5575
123. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Vibhagool A. Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand. J Infect 2006;52(3):188-94 (Pubitemid 43286185)
124. Manosuthi W, Chottanapand S, Thongyen S, et al. Survival rate and risk factors of mortality among HIV/ tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006;43(1):42-6 (Pubitemid 44306486)
125. Velasco M, Castilla V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009;50(2):148-52
126. Sanguanwongse N, Cain KP, Suriya P, et al. Antiretroviral therapy for HIV-infected tuberculosis patients saves lives but needs to be used more frequently in Thailand. J Acquir Immune Defic Syndr 2008;48(2):181-9
127. Tabarsi P, Saber-Tehrani AS, Baghaei P, et al. Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV. J Int AIDS Soc 2009;12(1):14
128. Yotebieng M, Van Rie A, Moultrie H, et al. Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. AIDS 2010;24(9):1341-9
129. Blanc FXea. Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severly immunocompromised HIV-infected adults with newly diagnosed tuberculosis. 18th International AIDS Conference. Vienna 2010
130. Toibaro JJ, Losso MH. Pharmacokinetics interaction studies between rifampicin and protease inhibitors: methodological problems. AIDS 2008;22(15):2046-7
131. Grange J, Adhikari M, Ahmed Y, et al. Tuberculosis in association with HIV/ AIDS emerges as a major nonobstetric cause of maternal mortality in Sub-Saharan Africa. Int J Gynaecol Obstet 2010;108(3):181-3
132. Lalloo UG, Ambaram A. New antituberculous drugs in development. Curr HIV/AIDS Rep 2010;7(3):143-51
133. Bonora S, Mondo A, Trentini L, et al. Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins. J Infect 2008;57(1):78-81
134. Granich R, Akolo C, Gunneberg C, et al. Prevention of tuberculosis in people living with HIV. Clin Infect Dis 2010;50(Suppl 3):S215-22